Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18 years, ≤70 years, male or female;~* Advanced collecting duct carcinoma of the kidney is diagnosed histologically or pathologically ;~* Have not received anti-angiogenesis targeted drug therapy and systemic chemotherapy;~* Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors);~* Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1;~* The expected life span is ≥12 weeks;~* No contraindications for chemotherapy, with enough liver function and renal function and normal ECG recording.Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90 g/L;Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN); For patients with non-metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN;~* The patients participate voluntarily and have signed the informed consent form.~Exclusion Criteria:~* Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures;~* Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds;~* Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension;~* Patients with a history of HIV infection or active phase of chronic hepatitis B/C;~* negative imaging examination result 4 weeks prior to enrollment);~* Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs);~* A history of allogeneic organ transplantation;~* Patients with evidence of hemorrhagic constitution or a past history of hemorrhage;~* Patients currently receiving renal dialysis;~* Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment;~* Patients participating in other clinical trials simultaneously;~* Other conditions unsatisfying the inclusion criteria in the investigator's opinions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sorafenib combined with chemotherapy (Type: EXPERIMENTAL): this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).